| Dr John Bond Murphy Jr, MD | |
|
507 N Lindsay St, High Point, NC 27262-4303 | |
| (336) 883-0029 | |
| Not Available |
| Full Name | Dr John Bond Murphy Jr |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 42 Years |
| Location | 507 N Lindsay St, High Point, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972565646 | NPI | - | NPPES |
| 8961545 | Medicaid | NC | |
| 10675 | Other | NC | BCBSNC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 27496 (North Carolina) | Primary |
| 207R00000X | Internal Medicine | 27496 (North Carolina) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bethany Medical Center | 4486614575 | 63 |
News Archive
iMDsoft® announced that Sunnybrook Health Sciences Centre in Canada is now live with the MetaVision clinical information system throughout their critical care environment. The system has been implemented in adult, neonatal and burn intensive care units, across a total of 145 beds.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, has received approval from the U.S. Food and Drug Administration for Ortho's VITROS Immunodiagnostic Products HBeAg Assay and the VITROS Immunodiagnostic Products Anti-HBe Assay for use on Ortho's VITROS 3600 Immunodiagnostic System and Ortho's VITROS 5600 Integrated System.
› Verified 3 days ago
| Entity Name | Bethany Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952404188 PECOS PAC ID: 4486614575 Enrollment ID: O20041013000729 |
News Archive
iMDsoft® announced that Sunnybrook Health Sciences Centre in Canada is now live with the MetaVision clinical information system throughout their critical care environment. The system has been implemented in adult, neonatal and burn intensive care units, across a total of 145 beds.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, has received approval from the U.S. Food and Drug Administration for Ortho's VITROS Immunodiagnostic Products HBeAg Assay and the VITROS Immunodiagnostic Products Anti-HBe Assay for use on Ortho's VITROS 3600 Immunodiagnostic System and Ortho's VITROS 5600 Integrated System.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Bond Murphy Jr, MD 645 N Main St, High Point, NC 27260-5017 Ph: (336) 883-0029 | Dr John Bond Murphy Jr, MD 507 N Lindsay St, High Point, NC 27262-4303 Ph: (336) 883-0029 |
News Archive
iMDsoft® announced that Sunnybrook Health Sciences Centre in Canada is now live with the MetaVision clinical information system throughout their critical care environment. The system has been implemented in adult, neonatal and burn intensive care units, across a total of 145 beds.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.
Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, has received approval from the U.S. Food and Drug Administration for Ortho's VITROS Immunodiagnostic Products HBeAg Assay and the VITROS Immunodiagnostic Products Anti-HBe Assay for use on Ortho's VITROS 3600 Immunodiagnostic System and Ortho's VITROS 5600 Integrated System.
› Verified 3 days ago
Melissa Joy Shelton, Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1580 Skeet Club Rd Ste 112, High Point, NC 27265 Phone: 336-883-0029 Fax: 336-883-0867 | |
Patrick J Watterson, PA-C Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 507 N Lindsay St, High Point, NC 27262 Phone: 336-883-0029 Fax: 336-883-0867 |